Network Insights Methodology Get Access

Novo Nordisk

ORG Health Care / Pharmaceuticals Momentum 5.8ML Momentum Score (0-100). Weighted composite of 9 features: mention velocity, article breadth, relationship density, deal context, recency, market cap, enrichment completeness, mention concentration, entity type. QUIETPSI regime classification. QUIET (<0.3): baseline activity. NORMAL (0.3-0.5): typical deal flow. ELEVATED (0.5-0.7): above-average signals. HIGH (0.7-0.85): significant activity. EXTREME (>0.85): exceptional signal concentration. Primary: Spectral Shift

$54B revenue (Copenhagen) manufactures insulin, GLP-1 obesity drugs, and hemophilia treatments across 80 countries. Semaglutide sales surged 97% in 2025 amid global obesity treatment demand expansion.

-1.11
PSI ScorePlocamium Signal Index - composite z-score from 5 orthogonal signals: news frequency, targeted sentiment, graph centrality, regulatory filings, and clinical trial activity.
5.8
MomentumML Momentum Score (0-100). Weighted composite of 9 features including mention velocity, article breadth, deal context, and relationship density. Retrained weekly.
1%
ConfidenceSignal confidence - percentage of PSI sub-signals with sufficient data (30+ observations). Higher confidence means the PSI score is based on more complete data.
19
ConnectionsDegree centrality - number of unique entities this entity co-occurs with in news signals and articles. Higher = more connected in the intelligence network.
Connected Entities
FDA China Eli Lilly PlocamiumAI United States India Canada OpenAI CEO AstraZeneca European Union Samsung Americans Merck Bloomberg
Watch This Entity
PSI Intelligence
30-Day Trend
2026-04-28 2026-05-28 19 0 Degree Mentions
Signal Decomposition
Attention Cascade
-0.000
Narrative Drift
0.000
Spectral Shift
1184.899
Sentiment-Momentum Divergence
0.000
Source Concentration
0.355
Peer Comparison
Not yet ranked. Sector-relative scoring requires at least four entities in the same BICS sector with PSI history; this entity does not yet meet the threshold or sits in a sector with insufficient peers.
Network Analysis
19 Degree Centrality
Ego Network (top connections)
FDA (weight 23.0)China (weight 14.0)Eli Lilly (weight 13.0)PlocamiumAI (weight 10.0)United States (weight 10.0)India (weight 8.0)Canada (weight 6.0)OpenAI (weight 4.0) FDAChinaEli LillyPlocamiumAIUnited StatesIndiaCanadaOpenAI Novo Nordisk (degree 19) Novo Nordisk
Centrality History
2026-04-28 2026-05-28 19 0 Degree Mentions
EntityWeight StatusFirst Seen
FDA 23 NEW
China 14 NEW
Eli Lilly 13 NEW
PlocamiumAI 10 NEW
United States 10 NEW
India 8 NEW
Canada 6 NEW
OpenAI 4 NEW
CEO 3 NEW
AstraZeneca 3 NEW
European Union 3 NEW
Samsung 2 NEW
Americans 2 NEW
Merck 2 NEW
Bloomberg 2 NEW
Wall Street 2 NEW
Netflix 2 NEW
Investing.com 2 NEW
Roche 1 NEW
Article Coverage (20)
DateLaneTitle
2026-05-09 Industrials & Manufacturing Lilly Shifts From Offshore Production to Indiana as GLP-1 Demand Outpaces Industry Output
2026-04-20 Healthcare M&A Novo Nordisk's Sickle Cell Therapy Hits in Phase 3, but Data Lag Expectations
2026-04-20 Healthcare M&A Novo Nordisk's Sickle Cell Therapy Hits in Phase 3, but Data Lag Expectations
2026-04-20 Healthcare M&A Novo Nordisk's Sickle Cell Therapy Hits in Phase 3, but Data Lag Expectations
2026-04-17 Healthcare M&A Walmart Expands Digital Health Platform's Weight Loss Offerings, Including GLP-1 Prescribing
2026-04-16 Geopolitics / GCC / LATAM China to Drive a Weight-Loss Drug Price War
2026-04-04 Healthcare M&A Pharma's Dealmaking Tear; Blackstone Raises Record Fund; Xolair Energizes Allergy Research; and More
2026-04-02 Healthcare M&A WHOOP Secures $575M, Reaches $10B Valuation
2026-04-01 Healthcare M&A Eli Lilly Wins Approval of Anti-Obesity Pill Orforglipron
2026-04-01 Healthcare M&A Eli Lilly Wins Approval of Anti-Obesity Pill Orforglipron
2026-04-01 Healthcare M&A Eli Lilly Wins Approval of Anti-Obesity Pill Orforglipron
2026-04-01 Healthcare M&A Eli Lilly Wins Approval of Anti-Obesity Pill Orforglipron
2026-03-30 Healthcare M&A Kailera Plans IPO For Phase 3 Obesity Drug From Hengrui
2026-03-30 Healthcare M&A Kailera Plans IPO For Phase 3 Obesity Drug From Hengrui
2026-03-30 Healthcare M&A Kailera Plans IPO For Phase 3 Obesity Drug From Hengrui
2026-03-30 Healthcare M&A Kailera Plans IPO For Phase 3 Obesity Drug From Hengrui
2026-03-26 Healthcare M&A Eli Lilly's Deal Man, Allogene's Off-The-Shelf CAR-T, and Merck's Terns Buy
2026-03-26 Healthcare M&A Oral Peptides Biotech Pinnacle Medicines Gets $89M From US, China Investors
2026-03-26 Healthcare M&A Oral Peptides Biotech Pinnacle Medicines Gets $89M From US, China Investors
2026-03-21 Healthcare Marketing FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide

Request Access

Full PSI intelligence, network analysis, EDGAR filings, and predicted links require an access token.

Data as of 2026-05-28 ← Intelligence Network